Masimo Co. (NASDAQ:MASI) has received a consensus rating of “Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $101.00.
MASI has been the subject of several analyst reports. Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a report on Tuesday, March 6th. Piper Jaffray Companies reiterated a “hold” rating and issued a $91.00 price objective on shares of Masimo in a report on Thursday, March 1st. BidaskClub upgraded Masimo from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Finally, Barclays initiated coverage on Masimo in a report on Friday, March 9th. They issued an “overweight” rating and a $97.00 price objective for the company.
Masimo (NASDAQ MASI) opened at $89.44 on Wednesday. Masimo has a twelve month low of $80.69 and a twelve month high of $104.71. The firm has a market capitalization of $4,620.00, a price-to-earnings ratio of 28.48, a PEG ratio of 2.32 and a beta of 0.91.
In related news, EVP Yongsam Lee sold 10,000 shares of Masimo stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $88.17, for a total value of $881,700.00. Following the completion of the sale, the executive vice president now directly owns 75,018 shares in the company, valued at approximately $6,614,337.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Sanford Fitch sold 2,000 shares of Masimo stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $90.00, for a total value of $180,000.00. Following the completion of the sale, the director now owns 70,249 shares of the company’s stock, valued at $6,322,410. The disclosure for this sale can be found here. Insiders sold a total of 24,000 shares of company stock valued at $2,177,340 over the last quarter. 13.10% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in MASI. Crossmark Global Holdings Inc. purchased a new position in Masimo in the third quarter worth about $645,000. Stevens Capital Management LP purchased a new position in Masimo in the third quarter worth about $1,255,000. Oregon Public Employees Retirement Fund boosted its position in Masimo by 6.2% in the third quarter. Oregon Public Employees Retirement Fund now owns 17,781 shares of the medical equipment provider’s stock worth $1,539,000 after purchasing an additional 1,037 shares during the last quarter. Principal Financial Group Inc. boosted its position in Masimo by 4.9% in the third quarter. Principal Financial Group Inc. now owns 206,175 shares of the medical equipment provider’s stock worth $17,847,000 after purchasing an additional 9,617 shares during the last quarter. Finally, Swiss National Bank boosted its position in Masimo by 1.9% in the third quarter. Swiss National Bank now owns 81,300 shares of the medical equipment provider’s stock worth $7,037,000 after purchasing an additional 1,500 shares during the last quarter. 82.84% of the stock is currently owned by institutional investors and hedge funds.
Masimo Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.